中國國藥疫苗 - 阿聯酋公司將從4月開始生產

Recently Yahoo News on-line reported the following:

UAE firm to manufacture Chinese Sinopharm vaccine from April

Reuters Sun., March 28, 2021, 7:07 a.m.

DUBAI, March 28 (Reuters) - A firm based in the United Arab Emirates will start commercial production of China's Sinopharm vaccines in April, under a deal announced on Sunday.

Gulf Pharmaceutical Industries PSC, based in the emirate of Ras al-Khaimah, signed the deal with Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42), which handled Phase III late-stage clinical trials of a Sinopharm vaccine in the UAE and the wider region.

The announcement is an expansion of Chinese diplomacy in the Gulf region and helps the UAE's quest to diversify its economy away from hydrocarbon production.

Chinese Foreign Minister Wang Yi has just completed a two-day official visit to the UAE, saying Beijing wanted to work with the UAE on producing affordable COVID-19 vaccines.

According to a Julphar filing on the Abu Dhabi stock exchange, the manufacturing agreement was made between Julphar and G42 Medications Trading.

G42 has previously said it has distribution and manufacturing agreements with Sinopharm and hopes to provide the UAE and other states in the region with the vaccine. G42 did not immediately respond to a request for more details.

The government of Ras al-Khaimah owns 12.24% of Julphar, according to Refinitiv data.

G42 began Phase III clinical trials of the vaccine developed by the Beijing Institute of Biological Product, a unit of Sinopharm's China National Biotec Group (CNBG), in July.

The UAE approved the vaccine for certain groups in September before making it available to the general public.

It has said the vaccine has 86% efficacy, while the Chinese developer has claimed 79.34% efficacy based on an interim analysis of late-stage trials.

Some people in the UAE failed to develop antibodies after a second dose of the Sinopharm vaccine and were given a third dose, the health ministry said this month. It said the number was "minimal" compared to the number of vaccines administered. (Writing by Lisa Barrington; Editing by Kevin Liffey)

Translation

(路透) 迪拜3月28日- 根據周日宣布的一項協議，位於阿拉伯聯合酋長國的一家公司將在4月開始商業生產中國國藥疫苗。

總部位於拉斯·海瑪（Ras al-Khaimah）酋長國的海灣製藥工業PSC與總部位於阿布扎比的人工智能和雲計算公司Group 42（G42）簽署了該協議。該公司處理國藥疫苗在阿聯酋和更廣泛的地區的III期後期臨床試驗。

這項宣布是中國在海灣地區外交的擴展，並幫助阿聯酋尋求使經濟從碳氫化合物生產轉向多元化。

中國外交部長王毅剛剛結束了對阿聯酋的為期兩天的正式訪問，他說北京希望與阿聯酋合作生產負擔得起的COVID-19疫苗。

根據Julphar在阿布扎比證券交易所的備案文件，製造協議是Julphar與G42 Medications Trading之間達成的。

G42此前曾表示已與國藥集團達成分銷和生產協議，並希望向阿聯酋和該地區其他州提供疫苗。 G42沒有立即回應要求提供更多詳細信息的請求。

根據Refinitiv的數據，拉斯·海瑪（Ras al-Khaimah）政府擁有Julphar 12.24％的股份。

G42於7月份開始對由國藥控股的中國國家生物技術集團（CNBG）旗下的北京生物產品研究所開發的疫苗進行III期臨床試驗。

阿聯酋在9月份批准了針對某些人群的疫苗後，然後才向公眾提供。

據說該疫苗的功效為86％，而中國開發者根據後期試驗的中期分析聲稱其功效為79.34％。

衛生部本月表示，阿聯酋有些人在第二次注射國藥疫苗後仍未能產生抗體，要給第三次注射。它說，與總接種疫苗的數量相比，該數量是“微不足道”的。

              So, China will have a foothold in the Middle East to produce and sell its Covid-19 vaccine. About a month ago, Russia has already received an approval to produce Sputnik 5 vaccine in Italy in Europe. Covid-19 vaccine is more than just about health-care, it is also related to politics and business. The demand for this vaccine will be a repeating and continuous matter for a very long time to come, globally.